MELATONIN LEVELS IN PATIENTS WITH ATRIAL FIBRILLATION – PILOT
RESULTS.

a 2024

MELATONIN LEVELS IN PATIENTS WITH ATRIAL FIBRILLATION – PILOT RESULTS.

MELAJOVÁ, Katarína; Katerina SKÁLOVÁ; Veronika BEDNÁROVÁ; Jan MÁCHAL; Zdeněk STÁREK et al.

Základní údaje

Originální název

MELATONIN LEVELS IN PATIENTS WITH ATRIAL FIBRILLATION – PILOT RESULTS.

Název česky

PROFIL HLADINY MELATONINU U PACIENTŮ S FIBRILÁCÍ SÍNÍ – PILOTNÍ VÝSLEDKY

Autoři

MELAJOVÁ, Katarína; Katerina SKÁLOVÁ; Veronika BEDNÁROVÁ; Jan MÁCHAL; Zdeněk STÁREK; Zdeňka BENDOVÁ a Martin PEŠL

Vydání

Czech Cardiovascular Research and Innovation Days 2024, 2024

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00137449

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Melatonin

Změněno: 19. 12. 2025 12:32, Mgr. Petra Trembecká, Ph.D.

Anotace

V originále

Introduction: Atrial fibrillation is linked to atrial fibrosis, inflammation, and oxidative stress. To date, the sleep hormone melatonin has not been explicitly associated with atrial fibrillation, despite its recognized antioxidant, anti-fibrotic, and anti-inflammatory properties. A recent study conducted on mice in 2022 demonstrated that melatonin plays a role in partially inhibiting the aforementioned processes involved in the development of atrial fibrillation. However, the endogenous levels of melatonin in patients with atrial fibrillation remain undescribed in the existing literature. The present study aims to investigate the melatonin profiles of patients with atrial fibrillation and to compare these profiles with those of healthy control subjects. Methods: Saliva samples were collected within a 24-hour period according to a predetermined schedule (10:00, 13:00, 16:00, 19:00, 22:00, 01:00, 04:00, 07:00, 10:00) using specially marked tubes and adhering to strict protocol measures. Following collection, the samples were frozen and subsequently transported to the laboratory for analysis via radioimmunoassay. After measurement, the melatonin levels were statistically evaluated. Results: In the pilot group of patients (n = 13) and controls (n = 10), melatonin concentrations were found to be reduced in patients with atrial fibrillation compared to controls. Additionally, patients with atrial fibrillation exhibited a lower amplitude of melatonin production. Conclusion: Atrial fibrillation has been associated with decreased levels of melatonin in a pilot cohort of patients. Melatonin may serve as a protective factor against fibrotic changes and might play a role in mitigating inflammatory and oxidative processes. Supported by CarDia and EXCELES, No. LX22NPO5104 and MUQUABIS GA no. 101070546. and MUNI/A/1624/2023

Návaznosti

MUNI/A/1624/2023, interní kód MU

Název: Srdeční selhání, jeho komorbidity a etiologické příčiny

Investor: Masarykova univerzita, Srdeční selhání, jeho komorbidity a etiologické příčiny

Citovat

MELAJOVÁ, Katarína; Katerina SKÁLOVÁ; Veronika BEDNÁROVÁ; Jan MÁCHAL; Zdeněk STÁREK; Zdeňka BENDOVÁ a Martin PEŠL. MELATONIN LEVELS IN PATIENTS WITH ATRIAL FIBRILLATION – PILOT RESULTS. In Czech Cardiovascular Research and Innovation Days 2024. 2024.

@proceedings{2446501,
   author = {Melajová, Katarína and Skálová, Katerina and Bednárová, Veronika and Máchal, Jan and Stárek, Zdeněk and Bendová, Zdeňka and Pešl, Martin},
   booktitle = {Czech Cardiovascular Research and Innovation Days 2024},
   keywords = {Melatonin},
   language = {eng},
   title = {MELATONIN LEVELS IN PATIENTS WITH ATRIAL FIBRILLATION – PILOT RESULTS.},
   url = {https://www.cksonline.cz/czech-cardiovascular-research-and-innovation-day-2024/sjezd.php?p=read_abstrakt_program&idabstrakta=54},
   year = {2024}
}

TY  - CONF
ID  - 2446501
AU  - Melajová, Katarína - Skálová, Katerina - Bednárová, Veronika - Máchal, Jan - Stárek, Zdeněk - Bendová, Zdeňka - Pešl, Martin
PY  - 2024
TI  - MELATONIN LEVELS IN PATIENTS WITH ATRIAL FIBRILLATION – PILOT RESULTS.
KW  - Melatonin
UR  - https://www.cksonline.cz/czech-cardiovascular-research-and-innovation-day-2024/sjezd.php?p=read_abstrakt_program&idabstrakta=54
N2  - Introduction: Atrial fibrillation is linked to atrial fibrosis, inflammation, and oxidative stress. To date, the sleep hormone melatonin has not been explicitly associated with atrial fibrillation, despite its recognized antioxidant, anti-fibrotic, and anti-inflammatory properties. A recent study conducted on mice in 2022 demonstrated that melatonin plays a role in partially inhibiting the aforementioned processes involved in the development of atrial fibrillation. However, the endogenous levels of melatonin in patients with atrial fibrillation remain undescribed in the existing literature. The present study aims to investigate the melatonin profiles of patients with atrial fibrillation and to compare these profiles with those of healthy control subjects. Methods: Saliva samples were collected within a 24-hour period according to a predetermined schedule (10:00, 13:00, 16:00, 19:00, 22:00, 01:00, 04:00, 07:00, 10:00) using specially marked tubes and adhering to strict protocol measures. Following collection, the samples were frozen and subsequently transported to the laboratory for analysis via radioimmunoassay. After measurement, the melatonin levels were statistically evaluated. Results: In the pilot group of patients (n = 13) and controls (n = 10), melatonin concentrations were found to be reduced in patients with atrial fibrillation compared to controls. Additionally, patients with atrial fibrillation exhibited a lower amplitude of melatonin production. Conclusion: Atrial fibrillation has been associated with decreased levels of melatonin in a pilot cohort of patients. Melatonin may serve as a protective factor against fibrotic changes and might play a role in mitigating inflammatory and oxidative processes. Supported by CarDia and EXCELES, No. LX22NPO5104 and MUQUABIS GA no. 101070546. and MUNI/A/1624/2023
ER  -

MELAJOVÁ, Katarína; Katerina SKÁLOVÁ; Veronika BEDNÁROVÁ; Jan MÁCHAL; Zdeněk STÁREK; Zdeňka BENDOVÁ a Martin PEŠL. MELATONIN LEVELS IN PATIENTS WITH ATRIAL FIBRILLATION – PILOT RESULTS. In \textit{Czech Cardiovascular Research and Innovation Days 2024}. 2024.

Přehled o publikaci